BeOne Medicines (ONC) Capital Expenditures (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Capital Expenditures data on file, last reported at $43.2 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 27.93% year-over-year to $43.2 million in Q1 2026; TTM through Mar 2026 was $40.5 million, a 254.35% increase from a year earlier, with the FY2025 full-year figure at $57.3 million, down 18.53% from the prior year.
• Capital Expenditures for Q1 2026 stood at $43.2 million, up from -$91.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for ONC reached as high as $183.0 million in Q2 2023 and fell as low as -$139.4 million in Q3 2023.
• Historically, Capital Expenditures has averaged $34.6 million across 5 years, with a median of $43.2 million in 2026.
• Across the five-year window, Capital Expenditures surged 1251.36% in 2023 and sank 1719.59% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $121.4 million in 2022, then sank by 113.03% to -$15.8 million in 2023, then soared by 68.35% to -$5.0 million in 2024, then sank by 1719.59% to -$91.0 million in 2025, then jumped by 147.51% to $43.2 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $43.2 million in Q1 2026, -$91.0 million in Q4 2025, and $48.1 million in Q3 2025.